The IL1B Knockout A2780 Polyclonal Cells constitute a polyclonal CRISPR/Cas9-edited population of A2780 human ovarian carcinoma cells with targeted disruption of the IL1B gene, eliminating both intracellular pro-interleukin-1?? and mature secreted IL-1??. This heterogeneous knockout pool enables loss-of-function studies without the selection biases of single-cell clones, offering a robust system for functional genomics in an epithelial adenocarcinoma background.
The A2780 cell line was isolated from an untreated patient with ovarian adenocarcinoma and has become a cornerstone model for ovarian cancer research, particularly in investigations of acquired chemoresistance. Its well-characterized epithelial morphology and responsiveness to platinum-based agents make it an ideal host for genetic modifications aimed at deciphering pathways that modulate drug sensitivity. In the context of IL1B knockout, A2780 provides a clinically relevant backdrop to study how inflammatory signaling influences tumor cell-autonomous processes and therapeutic responses.
IL1B encodes interleukin-1??, a central pro-inflammatory cytokine that orchestrates innate immune responses. Its expression is induced by Toll-like receptor 4 (TLR4), tumor necrosis factor (TNF), and NF-??B upon sensing pathogen-associated molecular patterns (PAMPs). The inactive pro-IL-1?? precursor is cleaved by caspase-1 (CASP1) after NLRP3 inflammasome assembly. Secreted IL-1?? binds the interleukin-1 receptor type 1 (IL1R1) in complex with interleukin-1 receptor accessory protein (IL1RAP), initiating MYD88-dependent signaling. This cascade recruits interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6), ultimately activating I??B kinase ?? (IKBKB) and mitogen-activated protein kinases (MAPKs). These pathways drive transcription of downstream pro-inflammatory genes such as IL6, CXCL8 (IL8), PTGS2 (COX2), and NFKBIA, while regulatory molecules like interleukin-1 receptor antagonist (IL1RA) and decoy receptor IL1R2 modulate signal strength.
Within the A2780 ovarian carcinoma background, IL-1?? signaling is implicated in promoting malignant phenotypes including cell survival, epithelial-mesenchymal transition, and resistance to platinum-based chemotherapies. Autocrine IL-1?? production can suppress apoptosis and foster a pro-tumorigenic microenvironment, while paracrine signals from infiltrating immune cells further shape disease progression. IL1B knockout in this model provides a clean loss-of-function system to dissect the tumor-intrinsic roles of IL-1??, distinct from stromal-derived cytokine effects. This tool enables precise interrogation of the intersection between inflammatory and oncogenic pathways in ovarian cancer.
Typical applications include quantitative analysis of inflammatory mediators by RT-qPCR and ELISA, NF-??B reporter assays, and caspase-1 activity measurements. The cells are suited for co-culture experiments with macrophages to study paracrine signaling, and for drug sensitivity screens with cisplatin to evaluate IL-1??-dependent chemoresistance. This polyclonal knockout pool offers a versatile genetic tool for inflammation and ovarian cancer research. For technical queries or custom engineering requests, contact Ascent Research.
